eligibility_summary
Eligible: adults (≥18) with CD20+ DLBCL, relapsed/refractory after ≥2 lines incl anthracycline+anti‑CD20 or after auto‑HSCT, ≥1 measurable lesion, ECOG ≤1, adequate organs/venous access, contraception for 1 yr post‑infusion. Exclude: primary CNS lymphoma, malignancy <2 yrs, active HBV/HCV/HIV/syphilis, severe DVT/PE <3 mos or anticoagulated, uncontrolled infection, GvHD, serious CV/CNS dz <6 mos, pregnant/lactating, washout/noncompliance, prior engineered T‑cell or cell/gene therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: JWCAR201, an autologous CD19/CD20-directed CAR-T cell therapy, delivered as a single IV infusion after lymphodepleting chemotherapy with fludarabine (purine-analog antimetabolite) and cyclophosphamide (alkylating agent). Mechanism: patient T cells are genetically engineered to express chimeric antigen receptors that bind CD19 and CD20 on B cells, CAR signaling activates T-cell effector functions (proliferation, cytokine release, perforin/granzyme-mediated cytotoxicity) to kill lymphoma cells. Lymphodepletion reduces competing lymphocytes and supports in vivo CAR-T expansion/persistence. Targets: malignant B cells in DLBCL via surface antigens CD19 and CD20, with expected on-target depletion of normal B cells.